Chinese biotechnology firm Zhongyianke Biotech announced on Thursday that it has raised RMB250 million (US$36.35 million) in a series A round of financing from a group of investors including Chinese investment firm Shenzhen Qianhai Beizeng Asset Management. The new round also saw the participation of investors including the country’s technology-focused life science fund Efung Capital, […] Chinese Human Vaccine-Focused Biotech Firm Gets $36M In Series A Round comes originally from China Money Network. All Rights Reserved.